Alzheimer Disease - Therapy
Research News and Information

Saturday, November 21, 2009

DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

26 Oct 2009 CONTEXT: DNA beta-amyloid(1-42) (Abeta42) trimer immunization was developed to produce specific T helper 2 cell (T(H)2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Abeta42 ... Read more...

Taking advantage of the systemic immune system to cure brain diseases.

13 Oct 2009 The systemic immune system has the ability to modulate multiple brain functions, including autonomic responses, glial reactivity following neural injuries, and neuronal excitability. Immune stimuli also influence microglia subpopulations originating ... Read more...

The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.

12 Oct 2009 The beta-amyloid (Abeta) peptide is the major constituent of amyloid plaques in Alzheimer's disease (AD) brain and is likely to play a central role in the pathogenesis of this devastating neurodegenerative disorder. The beta-secretase, beta-site ... Read more...

Latest indexed articles for 'Alzheimer Disease - Therapy'

These are the very latest articles for this heading:

• DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. 26 Oct 2009
• Taking advantage of the systemic immune system to cure brain diseases. 13 Oct 2009
• The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. 12 Oct 2009
• Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. 29 Sep 2009
• [Effects of auricular acupuncture on the memory and the expression of ChAT and GFAP in model rats with Alzheimer's disease] 29 Sep 2009
• Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. 8 Sep 2009
• Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. 7 Sep 2009
• Immunotherapeutic strategies for Alzheimer's disease treatment. 30 Aug 2009
• [Information and communication technology interventions supporting carers of people with Alzheimer's disease: a literature review] 30 Aug 2009
• Defining and labeling disease-modifying treatments for Alzheimer's disease. 30 Aug 2009
• Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). 30 Aug 2009
• An update on treatment and prevention strategies for Alzheimer's disease. 30 Aug 2009
• Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. 29 Aug 2009
• The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. 24 Aug 2009
• [The role of blood-brain barrier in the pathogenesis of Alzheimer dementia--implications for immunological therapies for plaque dissolution] 12 Aug 2009
• Alzheimer disease in women: a clinical and genetics perspective. 30 Jul 2009
• [Neurogenesis as a therapeutic target for Alzheimer's disease] 30 Jul 2009
• [Immunotherapy of Alzheimer's disease by Abeta vaccination] 30 Jul 2009
• The media and cognitive health in our aging population. 30 Jul 2009
• States take on Alzheimer's disease. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Alzheimer Disease'

Definition: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Descriptor UI: D000544

Alternative terms: Alzheimer Disease; Disease, Alzheimer; Dementia, Senile; Dementias, Senile; Senile Dementia; Senile Dementias; Dementia, Primary Senile Degenerative; Senile Dementia, Alzheimer Type; Alzheimer Type Senile Dementia; Primary Senile Degenerative Dementia; Alzheimer's Disease; Disease, Alzheimer's; Dementia, Alzheimer Type; Alzheimer Type Dementia; Dementia, Presenile; Dementias, Presenile; Presenile Dementia; Presenile Dementias; Alzheimer Disease, Late Onset; Late Onset Alzheimer Disease; Alzheimer's Disease, Focal Onset; Focal Onset Alzheimer's Disease; Acute Confusional Senile Dementia; Senile Dementia, Acute Confusional; Alzheimer Disease, Early Onset; Early Onset Alzheimer Disease; Presenile Alzheimer Dementia; Alzheimer Dementia, Presenile; Dementia, Presenile Alzheimer;

Related Mesh Headings: Amyloid beta-Protein; Amyloid beta-Protein Precursor; Cerebral Amyloid Angiopathy; tau Proteins; Neurofilament Proteins; Aphasia, Primary Progressive; Kluver-Bucy Syndrome;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C10.228.140.380.100; C10.574.945.249; F03.087.400.100;

History Note: 1998(1963); for DEMENTIA, PRESENILE and DEMENTIA, PRIMARY DEGENERATIVE SENILE use DEMENTIA 1981-1999; for DEMENTIA SENILE use DEMENTIA 1966-1999